|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/22/20 THC Therapeutics, Inc. 10-Q 4/30/20 60:3.1M Discount Edgar/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 403K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 17K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 17K
28: R1 Cover HTML 50K
49: R2 Consolidated Balance Sheets HTML 89K
40: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
15: R4 Consolidated Statement of Operations (Unaudited) HTML 71K
29: R5 Consolidated Statements of Stockholders Deficit HTML 95K
(Unaudited)
51: R6 Consolidated Statement of Cashflows (Unaudited) HTML 95K
42: R7 Description of Business and History HTML 23K
13: R8 Basis of Presentation and Going Concern HTML 22K
32: R9 Summary of Significant Policies HTML 35K
26: R10 Fixed Assets HTML 25K
22: R11 Intangible Assets HTML 25K
36: R12 Advances From Related Parties HTML 29K
57: R13 Related Party Transactions HTML 24K
25: R14 Secured Notes Payable HTML 31K
21: R15 Convertible Notes Payable HTML 44K
35: R16 Convertible Notes Payable Related Party HTML 21K
56: R17 Derivative Liability HTML 29K
27: R18 Stock Warrants HTML 25K
20: R19 Shareholders Deficit HTML 42K
44: R20 Subsequent Events HTML 23K
48: R21 Summary of Significant Policies (Policies) HTML 79K
33: R22 Fixed Assets (Tables) HTML 24K
14: R23 Intangible Assets (Tables) HTML 25K
43: R24 Advances From Related Parties (Tables) HTML 29K
47: R25 Secured Notes Payable (Tables) HTML 30K
30: R26 Convertible Notes Payable (Tables) HTML 44K
12: R27 Derivative Liability (Tables) HTML 28K
41: R28 Stock Warrants (Tables) HTML 26K
50: R29 Basis of Presentation and Going Concern (Details HTML 26K
Narrative)
59: R30 Summary of Significant Policies (Details HTML 31K
Narrative)
37: R31 Fixed Assets (Details) HTML 30K
18: R32 Fixed Assets (Details Narrative) HTML 20K
23: R33 Intangible Assets (Details) HTML 28K
60: R34 Intangible Assets (Details Narrative) HTML 20K
38: R35 Advances From Related Parties (Details) HTML 28K
19: R36 Advances From Related Parties (Details Narrative) HTML 21K
24: R37 Related Party Transactions (Details Narrative) HTML 50K
58: R38 Secured Notes Payable (Details) HTML 24K
39: R39 Convertible Notes Payable (Details) HTML 36K
52: R40 Convertible Notes Payable Related Party (Details HTML 44K
Narrative)
45: R41 Derivative Liability (Details) HTML 27K
16: R42 Derivative Liability (Details 1) HTML 40K
34: R43 Stock Warrants (Details) HTML 46K
53: R44 Stock Warrants (Details Narrative) HTML 23K
46: R45 Shareholders' Deficit (Details Narrative) HTML 262K
17: R46 Subsequent Events (Details Narrative) HTML 61K
54: XML IDEA XML File -- Filing Summary XML 103K
55: EXCEL IDEA Workbook of Financial Reports XLSX 58K
6: EX-101.INS XBRL Instance -- thct-20200430 XML 1.03M
9: EX-101.CAL XBRL Calculations -- thct-20200430_cal XML 120K
11: EX-101.DEF XBRL Definitions -- thct-20200430_def XML 433K
8: EX-101.LAB XBRL Labels -- thct-20200430_lab XML 667K
10: EX-101.PRE XBRL Presentations -- thct-20200430_pre XML 575K
7: EX-101.SCH XBRL Schema -- thct-20200430 XSD 147K
31: ZIP XBRL Zipped Folder -- 0001477932-20-003485-xbrl Zip 95K
EXHIBIT 31.1
CERTIFICATIONS
I, Brandon Romanek, certify that:
| 1. | I have reviewed this Form 10-Q of THC Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
|
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
| ||
| (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
|
| ||
|
| (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| Date: June 22, 2020 | By: | /s/ Brandon Romanek |
|
|
|
|
| |
|
|
| Chief Executive Officer |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/22/20 | |||
| For Period end: | 4/30/20 | NT 10-Q | ||
| List all Filings | ||||